Transcriptional Analysis of Apoptotic Cerebellar Granule Neurons Following Rescue by Gastric Inhibitory Polypeptide Polypeptide

Barbara Maino 1, Maria Teresa Ciotti 2, Pietro Calissano 2 and Sebastiano Cavallaro 1,*

1 Functional Genomics Center, Institute of Neurological Sciences, Italian National Research Council, Via Paolo Gaifami 18, 95126 Catania, Italy; E-Mail: barbara.maino@functional-genomics.it
2 European Brain Research Institute, Via del Fosso di Fiorano 64, 00143 Roma, Italy; E-Mails: mariateresa.ciotti@cnr.it (M.T.C.); p.calissano@ebri.it (P.C.)

* Author to whom correspondence should be addressed; E-Mail: sebastiano.cavallaro@cnr.it; Tel.: +39-095-7436634; Fax: +39-095-7122426.

Received: 27 January 2014; in revised form: 4 March 2014 / Accepted: 17 March 2014 / Published: 1 April 2014

Abstract: Apoptosis triggered by exogenous or endogenous stimuli is a crucial phenomenon to determine the fate of neurons, both in physiological and in pathological conditions. Our previous study established that gastric inhibitory polypeptide (Gip) is a neurotrophic factor capable of preventing apoptosis of cerebellar granule neurons (CGNs), during its pre-commitment phase. In the present study, we conducted whole-genome expression profiling to obtain a comprehensive view of the transcriptional program underlying the rescue effect of Gip in CGNs. By using DNA microarray technology, we identified 65 genes, we named survival related genes, whose expression is significantly de-regulated following Gip treatment. The expression levels of six transcripts were confirmed by real-time quantitative polymerase chain reaction. The proteins encoded by the survival related genes are functionally grouped in the following categories: signal transduction, transcription, cell cycle, chromatin remodeling, cell death, antioxidant activity, ubiquitination, metabolism and cytoskeletal organization. Our data outline that Gip supports CGNs rescue via a molecular framework, orchestrated by a wide spectrum of gene actors, which propagate survival signals and support neuronal viability.

Keywords: apoptosis; cerebellar granule neurons (CGNs); gastric inhibitory polypeptide (Gip); gene expression; rescue; survival; transcriptional program; pathway
1. Introduction

Neuronal apoptosis represents a distinctive mode of programmed cell death that is characterized by an intrinsic suicide program, by which a neuron orchestrates its own destruction. It is characterized by specific biochemical and morphological events, including fragmentation of nuclear DNA, breakdown of the cellular cytoskeleton, cell shrinkage and pyknosis, and the bulging out of the plasma membrane (blebbing) leading to the formation of apoptotic bodies [1,2]. During normal nervous system development, physiologically appropriate neuronal loss contributes to a sculpting process that removes approximately one-half of all neurons born during neurogenesis [3]. Neuronal loss subsequent to this developmental window is physiologically inappropriate for most systems and can contribute to neurological deficits, e.g., neurodegenerative diseases such as Alzheimer’s and Parkinson disease [2,4,5]. Elucidating the molecular mechanisms underlying neuronal apoptosis hence may contribute to our understanding of basic developmental biology and human neuropathology [6].

Cerebellar granule neurons (CGNs) represent, both in vivo and in vitro, a common model for the study of neuronal apoptosis [7–10]. Primary cultures of CGNs have been extensively utilized to examine the signal transduction mechanisms underlying neuronal apoptosis [11–13]. In this in vitro paradigm, CGNs undergo rapid apoptotic cell death within 24 h after removal of serum and lowering of extracellular potassium from 25 to 5 mM [8]. Apoptosis requires transcription and protein synthesis and becomes irreversible during the first six hours following induction. Before this “commitment point”, CGNs can be rescued by the activation of specific signal transduction pathways or by the treatment with specific neurotrophic factors [8,14–16]. Among these, we have recently showed that gastric inhibitory polypeptide (Gip) exerts a potent anti-apoptotic effect in cultured CGNs [16].

Gip is a 42-amino acid hormone, belonging to the glucagon superfamily of polypeptides and deriving from a 153-amino acid precursor [17–19]. In addition to its ability to regulate insulin secretion, Gip is known to exert a range of pleiotropic and extra-pancreatic actions [20–30]. Gip and its receptor show a widespread distribution in the central nervous system and have been implicated with neurogenesis, survival, synaptic plasticity and cognitive function [16,31–35]. The ability of Gip to regulate cell viability and apoptosis has been demonstrated in hippocampal and cerebellar granule neurons [16,36,37], as well as in β-cells [38–46] and osteoblasts [47]. Although the survival effects of Gip are initiated by a G-protein-coupled receptor and activate a variety of intracellular second messengers [48–50], these signaling pathways converge into the nucleus and regulate a transcriptional program governing cell life and death, which is still largely unknown. In this study we have used whole-genome expression analysis by DNA microarray technology to identify the complete spectrum of genes and pathways activated by Gip during the commitment phase of apoptosis of CGNs.

2. Results and Discussion

2.1. Whole-Genome Expression Changes Underlying Apoptosis Rescue by Gip

CGNs undergo apoptotic cell death after removal of serum and lowering of extracellular potassium from 25 to 5 mM [9] and can be rescued by Gip treatment. By using whole-genome oligonucleotide microarrays, we monitored whole gene expression profiles of CGNs six hours after induction of apoptosis or following rescue by a maximal effective dose (100 nM) of Gip.
When gene expression profiles in CGNs 6 h after induction of apoptosis (K5) were compared to those of apoptosis rescued CGNs (K5 + GIP), 65 genes showed significant changes of gene expression. The majority (53/65) of genes differently expressed during rescue by Gip (K5 vs. K5 + Gip) were also differentially expressed following induction of apoptosis (K25 vs. K5). Figure 1 shows the gene expression patterns of rescue genes organized in a hierarchical cluster. Although our data represent the average gene expression from four replicates, we confirmed the reliability of the microarray data by real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR). The expression pattern of four genes (Egr1, Nipal2, Fam171a2, Nptx1; differentially expressed in K5 or K5 + GIP) observed by microarrays closely paralleled the pattern observed using real-time PCR (Table 1).

In the following paragraphs, transcriptional changes implicated in the present study will be discussed within the framework of deregulated gene groups and are represented in Figure 2.

### 2.2. Deregulated Gene Groups

#### 2.2.1. Signal Transduction

The most numerous group of differentially expressed genes, after treatment of CGNs with Gip, encodes proteins involved in signal transduction, which are mostly up-regulated. To facilitate understanding of how the neuroprotective effect of the Gip could be converted into appropriate cellular responses, we divided the translated products by this gene group into subcellular compartments, including extracellular, transmembrane, cytoplasmic and nuclear molecules (Figure 2).

The extracellular proteins include two neuropeptides, Apelin (Apln) and Chemokine C-X3-C motif ligand 1 (Cx3cl1), and two secretory proteins, Cysteine-rich secretory protein LCCL domain containing 2 (Crispld2) and WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 1 (Wfikkn1), which are all up-regulated by Gip treatment.

Apln is a neuropeptide, known to prevent apoptosis in cortical neurons [51] and protect hippocampal neurons against NMDA receptor-mediated excitotoxicity [52–54]. Apln also enhances the protective effect of VEGF on H2O2-induced motor neuron death, whereas its deficiency accelerates motor neuron degeneration in the SOD1 (G93A) ALS mouse model [55]. Cx3cl1 is a neuron associated chemokine with neuroprotective effects in several in vivo and in vitro models of CNS pathology, including Parkinson’s disease [56–59]. Cx3cl1 attenuates excito-neurotoxicity and inhibits Fas-mediated cell death signaling [60–63]. Crispld2 is involved in neurogenesis, formation of normal neural crest cells and craniofacial development [64]. Wfikkn1 is a key inhibitor of Myostatin, which induces mitochondria-dependent apoptosis in the neuroblastoma cell line SH-SY5Y and slows muscle atrophy in the SOD1 (G93A) mice, an animal model of ALS [65–67].

A large group of transmembrane proteins is differentially expressed following Gip rescue. This group includes one over-expressed transmembrane adaptor protein, Shisa family member 8 (Shisa8), and six metabotropic receptors: Sema domain immunoglobulin domain transmembrane domain and short cytoplasmic domain (Sema4f), Interleukin 17 receptor E (Il-17re), Parathyroid hormone receptor 1 (Pthr1), Olfactory receptor 1462 (Olr1462) and Olfactory receptor 6 (Olr6) and Olfactory receptor 883 (Olr883). All of these metabotropic receptors are over-expressed, with the exception of Olr6 and Olr883.
Table 1. Validation of microarray data by real-time quantitative RT-PCR. Real-time PCR was used to validate the change in gene expression detected by microarray and to support the survival effects of Gip on CGNs.

| Name                                                | Genbank          | K25     | K5     | K5 + GIP | Forward primer                          | Reverse primer                          |
|------------------------------------------------------|------------------|---------|--------|----------|-----------------------------------------|------------------------------------------|
| Early growth response protein 1 (Egr1)               | U75397           | −0.94   | 0.11   | 1.58     | 5'-GGTGGGAATGCTGTTGACC-3'                | 5'-GCCAAACAGTCACCCTTGT-3'                |
| NIPA-like domain containing 2 (Nipal2)               | NM_001130559     | −1.26   | −0.22  | 0.71     | 5'-ACATGGGAGAAGCAACCTCTG-3'              | 5'-CTCCGTAATTGTGCAGCAGCT-3'              |
| Family with sequence similarity 171, member A2 (Fam171a2) | XM_001081512     | 0.11    | −0.63  | −1.58    | 5'-GGACAACGGTGACCGCAAT-3'                | 5'-TGGGGATCAGTTGAGGGAA-3'                |
| DEAD (Asp-Glu-Ala-Asp) box helicase 56 (Ddx56)       | NM_0010042112    | 0.35    | −0.53  | 0.18     | 5'-CTTGGGCTGCACCACCT-3'                 | 5'-ATTAGCCACTCTCACATCG-3'                |
| Zinc finger protein 423 (Zfp423)                      | XM_0010081512    | −1.23   | 0.27   | 0.59     | 5'-GGACAACGTGACCGTGAC-3'                | 5'-GTGCGTCATGCCCATCTCCAG-3'              |
| Neuronalpentraxin I (Nptx1)                         | NM_153735        | −1.50   | −0.39  | 1.14     | 5'-GGAGCTGATGGTTACATGG-3'                | 5'-ATAAGTCCACTGCAGCAGA-3'                |

Microarray (upper row): mean normalized value (Log scale); Quantitative RT-PCR (lower row): mean ± SEM of copies/100 pg RT-RNA.
**Figure 1.** Hierarchical clustering of genes differently expressed in CGNs treated with Gip, during the pre-commitment of apoptosis. Sixty-five rescue genes (differentially expressed in K5 vs. K5 + Gip), were named using their UniGene symbol and were ordered into a dendrogram, whose length of the branches represents the relatedness of the expression levels in different experimental conditions. Data are presented in a matrix format: each row is equivalent to a single gene and each column is equivalent to one of the three different experimental conditions (K25, K5, K5 + Gip). The color of the corresponding cell in the matrix indicates the averaged normalized intensity from replicates. Red, blue and white respectively represent transcript levels below, equal or above the median abundance across all conditions. Color intensity reflects the magnitude of the deviation from the median (see scale below). Rescue genes differently expressed also following induction of apoptosis (K25 vs. K5) are indicated by *.
**Figure 2.** A comprehensive picture showing expression changes associated with CGNs rescue by Gip treatment. Fifty out of sixty-five “Survival related genes” (SGRs) encode proteins with a known function. This figure represents the sub-cellular compartments and molecular processes of these proteins. Each encoded protein is labeled with a thermometer that indicates gene expression changes: downward thermometers have a blue color and indicate down-regulated expression, whereas upward thermometers have a red color and indicate up-regulated expression. In addition to the SGRs, this Figure includes other genes (without a thermometer), which are part of a specific pathway. The figure legend below shows the set of symbols whereby network objects and interactions between objects are indicated in the figure. Mechanism of physical interactions between objects is indicated as follows: (B), binding; (+P), phosphorylation; (Z), catalysis; (T), transformation; (TR), transcription; (CM), covalent modifications; (IE), influence on expression; and (?,) unspecified.
Antagonizing Wnt and FGF signaling, Shisa8 is necessary for brain development [68,69], whereas interacting with Shisa9 it promotes short-term plasticity [69]. Sema4f, which is a member of the class IV subgroup of the semaphorin family, plays a role in neural development and glutamatergic synaptic plasticity in cultured hippocampal neurons [70,71]. The cytokine membrane receptor II-17 rer exerts a great influence on adaptive immune cell recruitment in cases of CNS bacterial infection. High expression levels of II-17rer regulate the cellular mitogenesis via the RAS/MAPK signaling pathway, whereas a deficiency can induce CNS autoimmune disease [72–75]. Activation of the G-protein-coupled receptor Pthr1 elicits neuroprotective effects in rat cerebellar granule cells [76,77], regulating the L-type calcium channel and inhibiting kainic acid-induced excitotoxicity [78,79]. Similarly, Pthr1 expression in medulloblastoma protects from apoptosis [80]. Olr1462, Olr6 and Olr883 are members of the olfactory receptor family and as such play a role in the embryonic development of the human brain. Dysregulation of some cortical olfactory receptors has been associated with Parkinson disease [81].

Different genes, encoding for cytoplasmic proteins, are up-regulated following Gip treatment. This group includes two members of the phosphatidylinositol signaling pathway, Inositol polyphosphate-4-phosphatase type II (Inpp4b) and Pleckstrin homology domain containing, family O member 1 (Plekho1), one member of the type IV cyclic nucleotide phosphodiesterase (PDE) family,
Phosphodiesterase 4B, cAMP-specific (Pde4b) and one serine and threonine-specific protein kinase Zinc finger, MYND-type containing 8 (Zmynd8). Inpp4b plays a neuro-proliferative effect against neurotoxicity induced by aluminium chloride AlCl3 in the experimental model of Crocus sativus L. [82]. High expression levels of Plekho1 appear to play a novel anti-apoptotic role against TNF reverse signaling in THP-1 and HEK293 cells [83]. Conversely low expression levels of Pde4b promote apoptosis in non-neuronal cells, such as the 3-D colonic-crypt [84] and B-cell model [85], as well as in the microglial cell line BV-2 [86]. In addition, deregulation in intracellular signaling mediated by PDE4B has been reported in schizophrenia and bipolar disorder [87]. Interacting with a member of the REST co-repressors group (RCOR2), Zmynd8 inhibits neural differentiation in Xenopus embryos [88].

It is interesting to note that a splice-variant of the Zmynd8 gene, called Protein kinase C-beta2 (PKCb2a), regulates several cellular functions, including the inhibition of apoptosis [89].

In the cytoplasmic proteins subcategory, Gip induces two genes encoding synaptic proteins, SH3 and multiple ankyrin repeat domains 2 (Shank2) and Discs, large (Drosophila) homolog-associated protein 1 (Dlgap1) [90–93]. They both represent scaffolding proteins of excitatory synapses inside the CNS [93–95]. An increase in Shank2 expression and mutations of Shank2 have been reported in Alzheimer’s disease and in Plena McDermid Syndrome, respectively [96], whereas genetic variants in the Dlgap1 gene can induce schizophrenia [97].

Microarray screening of genes up-regulated in CGNs following Gip rescue highlighted four members of the nuclear proteins category: Prickle homolog 1 Drosophila (Prickle1), Pleckstrin homology-like domain, family A, member 1 (Phlda1), Coiled-coil domain containing 89 (Ccdc89) and Testis specific protein Y-linked 4 (Tspy4).

Prickle1 is a nuclear receptor, which positively regulates planar cell polarity (PCP), both in CNS neurons [98] and in murine neuroblastoma (C1300) cells [99,100], and facilitates cortical neurogenesis [98]. Depletion in Prickle1 expression has been reported in human progressive myoclonus epilepsy (PME) [98,101]. Phlda1 (Tdag51) is a member of the pleckstrin homology-like domain family and although its anti-apoptotic role has not yet been found in neuronal cells, its protective effect has been shown in NWTb3 fibroblast mouse [102] and in the oral cancer cell line Ca9-22 [103]. Moreover, deficiency of Phlda1 expression promotes oxidative stress induced-apoptosis in MEFs, a mouse model of embryonic fibroblasts [104]. In contrast, high expression levels of Phlda1 are correlated with the evolution of intractable epilepsy (IE) [105]. Ccdc89 is a potential regulator of neurogenesis, interacting with the orange domain of the hairy-related transcription factor (HRT/Hey1) in Xenopus and mouse [106]. The nuclear protein Tspy4 is a member of the Tspy (testis-specific protein Y-encoded) family and, as such, is a sperm-specific biomarker in human cervico-vaginal fluids [107]. However the recent discovery that Tspy1 is found together with the multi-domain adapter protein CASK in neuronal axon fibers in the brain [108] could be the starting point to further investigate the role of Tspy4 in the development of the brain.

2.2.2. Transcription

Microarray analysis showed that the Gip rescue regulates the expression of a considerable fraction of genes encoding proteins involved in transcriptional regulation, which can be divided into immediate-early and secondary-response genes.
The first subgroup includes the up-regulated *Immediate early response 5* (*Ier5*) and *Immediate early response 5-like* (*Ier5l*). *Ier5* regulates the cellular response to mitogenic signals [109]. Its expression increases in rat cerebral cortex after sleep deprivation or spontaneous waking [110] and may also be considered a regulator of circadian rhythms. *Ier5l* is related to cellular and embryonic development [111].

The secondary response genes subgroup includes three transcription factors, *Neuronal differentiation 2* (*NeuroD2*), *Ets variant gene 1* (*Etv1*), *Taf5 RNA polymerase II TATA box binding protein (TBP)-associated factor, 100 kDa* (*Taf5*), and two transcriptional regulators, *Immunoglobulin helicase μ-binding protein 2* (*Ighmbp2*) and *LIM domain only 2* (*rhombotin-like 1*) (*Lmo2*). All of these molecules are over-expressed by Gip treatment, with the exception of *Taf5*.

*NeuroD2* is a basic helix-loop-helix (bHLH) protein, a member of the NeuroD family, which has pleiotropic functions, including neurogenesis, neuronal differentiation, development, connectivity and synaptic maturation [112–117]. Its over-expression, in particular, has been related to the survival of cerebellar and hippocampal neurons [118]. Deficiency of *NeuroD2* in mice has been linked to amygdala dysfunction [116] and ataxia [117,118]. Similarly, a member of the ETS (E twenty-six) family, *Etv1*, controls a broad array of neuronal processes, including dopamine neuronal differentiation, maturation of granule cells by means of gene regulation (*Nrc2*, *Tiam2* genes and more others) and *Bdnf* cascade signaling [119–122]. *Etv1* induction also promotes sensory motor-circuitry [123], whereas *Etv1* deficiency has been reported in Spinal muscular atrophy [124]. Although the *Etv1* anti-apoptotic role in neurons has not been previously reported, its protective role has been demonstrated in the human breast cancer cell line MDA-MB-23 [125]. *Taf5* is an integral subunit of the TFIID transcription complex that is known to stabilize the interaction with *Taf6* [126], a pro-apoptotic protein which controls p53-apoptosis in human cells [127]. Down-regulation of *Taf5* following Gip treatment, therefore, may induce a rescue effect by interfering with *Taf6*.

The transcriptional regulator *Ighmbp2*, which is over-expressed by Gip treatment, is a member of the helicase superfamily. Its encoded protein regulates replication, recombination and repair processes [128]. Defects in DNA repair are very often involved in cell death and a lack of *Ighmbp2* may underlie altered DNA repair. In addition, several mutations of *Ighmbp2* have been reported in Distal Spinal Muscular Atrophy type 1 (DMSA) [129,130]. *Lmo2* controls cerebellum and hippocampal development and plays a role in neurogenesis, interacting with the pro-survival factors *Slc* and *Gata2* [131,132].

### 2.2.3. Cell Cycle

The Gip neuroprotective effect regulates the expression of two genes involved in cell cycle checkpoints: *Pds5*, *regulator of cohesion maintenance, homolog B* (*S. cerevisiae*) (*Pds5b*) and *Ino80 complex subunit* (*Ino80*). These two genes are both up-regulated following Gip treatment. *Pds5b* is a cohesion protein, known to pair replicated sister chromatids during cohesion in the S phase of the cell cycle [133,134]. Precise missense mutations of *Pds5b* have been associated to apoptosis in *saccharomyces cerevisiae* during early meiosis [135] and with the onset of Cornelia de Lange Syndrome (CdLS) [136]. *Ino80* is a member of the chromatin remodeler family, which plays an efficient role in DNA synthesis, S-phase progression and chromosome segregation during the normal cell division cycle [137]. In yeast, *Ino80* enhances chromatin mobility in response to DNA damage,
acting downstream from the checkpoint factor Mec [138], whereas it suppresses genome instability, modulating chromatin remodelling complexes and repairing DNA double-strand breaks via the expression of \( \text{Rad54B} \) and \( \text{XRCC3} \) genes [139].

2.2.4. Chromatin Remodelling

Two genes encoding proteins involved in chromatin remodelling are up-regulated by Gip during rescue of CGNs apoptosis: \( \text{Chromodomain protein Y-like 2 (Cdyl2)} \) and \( \text{TEN1 CST complex subunit (Ten1)} \).

\( \text{Cdyl2} \) is a member of the chromodomain Y chromosome (CDY) family and plays several roles, including histone modification and genome imprinting [140]. \( \text{Ten1} \) is a member of the trimeric CTS complex (telomere-capping complex), which is essential for genome stability [141–143]. Insufficient telomeric DNA length or deficiency of key telomere-associated factors is known to elicit a DNA damage response, resulting in cellular senescence or apoptosis [144].

2.2.5. Cell Death

Microarray analysis showed down-regulation of \( \text{Caspase 8 associated protein 2 (Casp8ap2)} \) following Gip treatment. This gene encodes a multifunctional protein of the cysteine proteases family, which orchestrates the formation of the death complex [145,146], interacting with caspase-8 and activating Fas-mediated apoptosis and histone mRNA 3’ end processing [147,148].

2.2.6. Antioxidant Activity

Gip rescue was associated with the up-regulation of a gene, \( \text{Cytoglobin (Cygb)} \), involved in the antioxidant defense system. The protein encoded by this gene is a member of the globin molecule family with a double functional nature: antioxidant activity, inducing superoxide dismutase, and anti-apoptotic activity, inhibiting the apoptotic effects of caspase-2 and caspase-3 [149–152]. In particular, \( \text{Cygb} \) plays a protective role against hypoxia-ischemia (HI) in rat brains [151] and safeguards cerebellar cells against chronic exposure to carbon monoxide (CO) during pre- and post-natal development [153].

2.2.7. Ubiquitination

During Gip rescue we observed the over-expression of two members of the CGNs ubiquitin-proteasome system: Zinc and ring finger 1 E3 ubiquitin protein ligase (\( \text{Znrf1} \)) and Ubiquitin specific peptidase 10 (\( \text{Usp10} \)).

\( \text{Znrf1} \) is a member of the ZNRF-E3 ubiquitin ligase family, which plays an important role in neuronal development, transmission, plasticity and also neuritogenesis by interacting with tubulin and glutamine synthetase (GS) [154–156]. Relevant to the present study is the previous demonstration that up-regulation of the \( \text{Znrf1} \) gene induces an anti-apoptotic effect in MOLT-4 leukemia cells [157]. \( \text{Usp10} \) is an ubiquitin-specific protease, which contributes to the formation of the stress granules interacting with GTPase-activating protein SH3 domain binding protein 1 (\( \text{G3BP1} \)) [158]. Stress granules are essential sites for translating stress-inducible genes and for reducing reactive oxygen species production [159].
2.2.8. Metabolism

Microarray analysis showed an over-expression of five genes, encoding respectively two members of the serine protease subgroup, Rhomboid 5 homolog 2 (Rhbd2) and Dipeptidyl-peptidase 3 (Dpp3), one aminoaacyl-tRNA synthetase, Leucyl-tRNA synthetase 2, mitochondrial (Lars2), one mitochondrial protein carrier, Solute carrier family 25 member 42 (Slc25a42) and one adipogenic protein, Mesenteric estrogen dependent adipogenesis (Medag).

Rhbd2 is a catalytically inactive member of the rhomboid family, which was recently reported as a key regulator of the anti-apoptotic TNF-alpha convertase enzyme (Adam17 or Tace) \[160,161\] that activates the transcription factor NF-kappa B in rat cortical neuron cultures after exposure to oxygen-glucose and glutamate deprivation \[160–162\]. Dpp3 is a member of the S9B peptidase family that is known to inhibit four pro-apoptotic genes, BCL2-like 10 (apoptosis facilitator) (BCL2L10), Tumor necrosis factor (ligand) superfamily, member 10 (TNFSF10), Tumor necrosis factor receptor superfamily, member 25 (TNFRSF25) and Tumor necrosis factor (ligand) superfamily, member 8 (TNFSF8) \[163\]. Dpp3 also activates the antioxidant response element (ARE) in primary mouse-derived cortical neurons, inducing NF-E2-related factor 2 (NRF2) nuclear translocation and NAD(P)H: quinoneoxidoreductase 1 \[164\]. Lars2 is a nuclear gene encoding the enzyme catalyzing the aminoacylation of mitochondrial tRNA (Leu) and its over-expression may represent an additional mechanism whereby CGNs contrast the induction of apoptosis and the partial inactivation of vital tRNA-Leu molecules \[165\]. In addition, over-expression of Lars2 in the human brain is a hallmark of a mitochondrial DNA point mutation (3243A > G) and may have a pathophysiological role in bipolar disorder and schizophrenia \[166\]. Slc25a42 is a novel member of the mitochondrial carrier family for coenzyme A (CoA) and adenosine 3’,5’-diphosphate \[167,168\] and is involved in the Stanley syndrome and Amish microcephaly \[169\]. Medag promotes adipogenesis and glucose uptake, interacting with several mediators, such as the fatty acid transporter CD36 that is involved in the uptake of the apoptotic material \[170,171\].

2.2.9. Cytoskeletal Organization

Following Gip treatment, we observed the differential expression of a number of genes whose encoded proteins are involved with cytoskeletal rearrangements, cell shape, and motility, as well as dendritic spines \[172\]. These genes segregate into three groups: cytoplasmic actin isoforms, actin-binding proteins and other manipulators of the cytoskeletal organization.

The group of cytoplasmic actin includes two genes over-expressed by Gip: Actin beta (Actb) and Actin, gamma 2, smooth muscle, enteric (Actg2). Actb is one of the six different actin isoforms in humans and regulates synaptic formation and neuronal plasticity, interacting with the RNA-binding protein Sam68 \[173,174\]. Actb also plays a neuroprotective effect in propriospinal neurons after axotomy and in the MCF-7 breast cancer cells following treatment with salicylic acid \[175\]. A deficit in Actb gene expression alters cytosplastic actin dynamicity and clinically induces Baraitser-Winter pathology and fragile X tremor/ataxia syndrome \[173,176\]. Consistent with the functions of other actin isoforms, Actg2 regulates the maintenance of the cytoskeleton, including actin-based motility in neurons \[177\]. Induction of Actg2, in particular, was found to rescue cardiac alpha-actin-deficient
mice [178], whereas Actg2 repression contributes to cell cycle arrest following cadmium treatment of human lung fibroblast [179].

The group of actin-binding proteins includes the over-expressed Coronin, actin binding protein, 2A (Coro2a) and Enah/Vasp-like (Evl). Coro2a is a member of the WD repeat protein family, which regulates motile processes, neuronal actin organization and focal-adhesion turnover through the cofilin signaling pathway [180,181]. Evl is a member of the Ena/VASP protein family, which enhances axon guidance, lamellipodial and filopodial dynamics in migrating cells, specifically binding the Sema6A-1 [182–184].

The group of manipulators of the cytoskeletal organization includes Leucine rich repeat containing 8 family, member D (Lrrc8d), PDZ and LIM domain 5 (Pdlim5), Epsin 3 (Epn3), Transmembrane protein 47 (Tmem47) and SH3 and PX domains 2A (Sh3pxd2a). All of these, with the exception of Sh3pxd2a, are over-expressed following Gip treatment.

Lrrc8d, a member of the leucine-rich repeat protein family, is involved in B-cell development [185] and regulates cell adhesion and cellular trafficking. Pdlim5 is a LIM domain protein, which is involved in cytoskeleton organization, synaptic development and plasticity [186]. Epn3, a member of the Epsin family, stimulates neurite outgrowth and brain development interacting with Epn1 [187]. Tmem47 is a member of the PMP22/EMP/claudin protein family [188], which is required in the formation and sealing capacity of cell junctions mostly in the kidney [189]. Up-regulation of Tmem47 inhibits neurite outgrowth and regulates neuronal differentiation [190]. The human TMEM47 is considered a likely candidate for X-linked mental retardation [188]. Sh3pxd2a is an adapter protein, which regulates the outgrowth of podosomes, a type of actin-rich structure involved in tumor invasion and in pro-apoptotic signals. Interacting with the metalloprotease ADAM12, Sh3pxd2a may confer susceptibility to late-onset Alzheimer’s disease [191–193].

3. Experimental Section

3.1. Materials

All the substances were obtained from Sigma Aldrich (Milano, Italy) unless otherwise specified.

3.2. Neuronal Cultures

CGNs were obtained from dissociated cerebella of eight-day-old Wistar rats (Charles River, Lecco, Italy) (P8) and cultured as previously described [194]. Cells were plated in basal Eagle’s medium supplemented with 10% fetal calf serum, 25 mM KCl, 2 mM glutamine and 100 μg/mL gentamycin in poly-L-lysine coated 24-well clusters (NUNC, VWR International PBI s.r.l., Milano, Italy). Granule neurons were plated at 0.5 × 106 cells/well in BME.

3.3. Microarray Experiments

After six days “in vitro” (DIV), extracellular KCl of CGNs was shifted from 25 to 5 mM for neuronal apoptotic death induction. After two washes with serum-free BME containing 5 mM KCl, neurons were incubated with the same medium for 6 h (K5), while control neurons were incubated with serum free medium supplemented with 25 mM KCl (K25). K5 neurons were also treated with a maximal effective dose of GIP. After six hours of incubation, total RNA was extracted with Trizol
(Life Technologies, Monza, Italy) from four biological replicates (derived from the same litter) for each of the experimental conditions (K25, K5, K5 + GIP). RNA integrity was confirmed by using a RNA chip and a 2100 Bioanalyzer (Agilent Technologies, Milano, Italy) with the protocol outlined by the manufacturer. Complementary RNAs (cRNAs) labeled with Cy3-CTP were synthesized from 1 μg of total RNA of each sample using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies, Milano, Italy) following the manufacturer’s protocol. Aliquots (750 ng) of Cy3 labeled cRNA targets were hybridized on Whole Rat Genome Oligo Microarrays (Agilent Technologies, Milano, Italy). Microarray hybridization and washing were performed using reagents and instruments (hybridization chambers and rotating oven) as indicated by the manufacturer. Microarrays were scanned at 5-μm resolution using a GenePix Personal 4100A microarray scanner and the GenePix Pro 6.0 acquisition and data-extraction software (Molecular Devices, Sunnyvale, CA, USA). Raw data were processed and analyzed with GeneSpringGX 12.5 (Agilent Technologies, Milano, Italy). To remove unreliable data, all genes from all samples were filtered for quality to include only probe data fulfilling all of the following criteria in all replicates of at least one out of four experimental conditions: the spot had <3% of saturated pixels at 532 nm; the spot was not flagged “bad”, “not found” or “absent”; the spot was detectable well above background (signal-to-noise ratios at 532 nm were >10). Filtering data by quality control criteria short-listed 29,892 genes as our complete data set, out of a total of 41,012 probes present on the microarray. Genes in our quality-filtered data set were screened by a one-way ANOVA using Welch’s \( t \)-test, followed by the Benjamini and Hochberg False Discovery Rate procedure as a multiple testing correction and the Tukey’s Post Hoc test. Genes with a corrected \( p \) value <0.05 were selected as differentially expressed genes.

3.4. Real Time Quantitative PCR

Following extraction, total RNA samples (three/experimental condition) were reverse transcribed with an oligo(dT)12-18 and SuperScript II Rnase H-reverse transcriptase (Life Technologies, Milano, Italy). Aliquots of cDNA (0.1 and 0.2 mg) and known amounts of external standard (purified PCR product, 102 to 108 copies) were amplified in parallel reactions using primers indicated in Table 1. To control for the integrity of RNA and for differences attributable to errors in experimental manipulation, mRNA levels of mouse ribosomal S18 and phosphoglycerate kinase 1 were measured in similar reactions. Each PCR reaction (final volume 20 mL) contained 0.5 mM of primers, 2.5 mM Mg\(^{2+}\) and 1× DNA SYBR Green master mix (Roche Diagnostics, Monza, Italy). PCR amplifications were performed with a Light-Cycler (Roche Diagnostics, Monza, Italy) using the following four cycle programs: (i) denaturation of cDNA (1 cycle: 95 °C for 1 min); (ii) amplification (40 cycles: 95 °C for 0 s, 57 °C for 5 s, 72 °C for 10 s); (iii) melting curve analysis (1 cycle: 95 °C for 0 s, 67 °C for 10 s, 95 °C for 0 s); (iv) cooling (1 cycle: 40 °C for 3 min). Temperature transition rate was 20 °C/s except for the third segment of the melting curve analysis where it was 0.2 °C/s. Fluorimeter gain value was 7. The sequence of forward and reverse gene specific primers is shown in Table 1. Real-time detection of fluorimetric intensity of SYBR Green I, indicating the amount of PCR product formed, was measured at the end of each elongation phase. Quantification was performed by comparing the fluorescence of PCR products of unknown concentration with the fluorescence of the external standards. For this analysis, fluorescence values measured in the log-linear phase of amplification were
considered using the second derivative maximum method of the Light Cycler Data Analysis software (Roche Diagnostics, Monza, Italy). Specificity of PCR products obtained was characterized by melting curve analysis followed by gel electrophoresis and DNA sequencing.

4. Conclusions

In the last years, the advent of full genome sequencing and high-throughput technologies are revolutionizing our ability to decode the underlying mechanisms of neuronal apoptosis and survival by offering a new approach based on systems biology. In this study we report for the first time a whole-genome analysis of these processes in CGNs following rescue by Gip. The results reveal the existence of a previously unknown transcriptional program associated with neuronal survival. The exact role and functional relationships of the genes implicated by gene expression profiling are mostly unknown and will require further studies. Systematic characterization of expression patterns associated to different rescue factors and in distinct temporal domains will also provide a framework for interpreting the biological significance of the expression patterns observed. Genetic or pharmacological exploitation of potential targets will help to determine their cause-relationship and identify new clues for neuroprotective drugs.

Acknowledgments

We gratefully acknowledge Cristina Calì, Alfia Corsino, Maria Patrizia D’Angelo and Francesco Marino for their administrative and technical support.

Author Contributions

B.M. carried out microarray and RT-PCR analysis, and drafted the manuscript; M.T.C. performed all neuronal cultures experiments, P.C. and S.C. conceived and designed the study. S.C. performed microarray data analysis.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Jellinger, K.A. Challenges in neuronal apoptosis. *Curr. Alzheimer Res.* **2006**, *3*, 377–391.
2. Arends, M.J.; Wyllie, A.H. Apoptosis: Mechanisms and roles in pathology. *Internatl. Rev. Exp. Pathol.* **1991**, *32*, 223–254.
3. Oppenheim, R.W. Cell death during development of the nervous system. *Annu. Rev. Neurosci.* **1991**, *14*, 453–501.
4. Pettmann, B.; Henderson, C.E. Neuronal cell death. *Neuron* **1998**, *20*, 633–647.
5. Mattson, M.P. Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. *Antioxid. Redox Signal.* **2006**, *8*, 1997–2006.
6. D’Mello, S.R.; Chin, P.C. Treating neurodegenerative conditions through the understanding of neuronal apoptosis. *Curr. Drug Targets* **2005**, *4*, 3–23.
7. Contestabile, A. Cerebellar granule cells as a model to study mechanisms of neuronal apoptosis or survival in vivo and in vitro. Cerebellum 2002, 1, 41–55.

8. D’Mello, S.R.; Galli, C.; Ciotti, T.; Calissano, P. Induction of apoptosis in cerebellar granule neurons by low potassium: Inhibition of death by insulin-like growth factor i and camp. Proc. Natl. Acad. Sci. USA 1993, 90, 10989–10993.

9. Gallo, V.; Ciotti, M.T.; Coletti, A.; Aloisi, F.; Levi, G. Selective release of glutamate from cerebellar granule cells differentiating in culture. Proc. Natl. Acad. Sci. USA 1982, 90, 7919–7923.

10. Isaev, N.K.; Stelmashook, E.V.; Halle, A.; Harms, C.; Lautenschlager, M.; Weih, M.; Dirnagl, U.; Victorov, I.V.; Zorov, D.B. Inhibition of Na⁺, K⁺-atpase activity in cultured rat cerebellar granule cells prevents the onset of apoptosis induced by low potassium. Neurosci. Lett. 2000, 283, 41–44.

11. Wood, K.A.; Dipasquale, B.; Youle, R.J. In situ labeling of granule cells for apoptosis-associated DNA fragmentation reveals different mechanisms of cell loss in developing cerebellum. Neuron 1993, 71, 621–632.

12. Tanaka, M.; Marunouchi, T. Immunohistochemical analysis of developmental stage of external granular layer neurons which undergo apoptosis in postnatal rat cerebellum. Neurosci. Lett. 1998, 242, 85–88.

13. Nikolic, M.; Gardner, H.A.; Tucker, K.L. Postnatal neuronal apoptosis in the cerebral cortex: Physiological and pathophysiological mechanisms. Neuroscience 2013, 254, 369–378.

14. Galli, C.; Meucci, O.; Scorziello, A.; Werge, T.M.; Calissano, P.; Schettini, G. Apoptosis in cerebellar granule cells is blocked by high kcl, forskolin, and igf-1 through distinct mechanisms of action: The involvement of intracellular calcium and rna synthesis. J. Neurosci. 1995, 15, 1172–1179.

15. Cavallaro, S.; Copani, A.; D’Agata, V.; Musco, S.; Petralia, S.; Ventra, C.; Stivala, F.; Travali, S.; Canonico, P.L. Pituitary adenylate cyclase activating polypeptide prevents apoptosis in cultured cerebellar granule neurons. Mol. Pharmacol. 1996, 50, 60–66.

16. Paratore, S.; Ciotti, M.T.; Basille, M.; Vaudry, D.; Gentile, A.; Parenti, R.; Calissano, P.; Cavallaro, S. Gastric inhibitory polypeptide and its receptor are expressed in the central nervous system and support neuronal survival. Cent. Nerv. Syst. Agent Med. Chem. 2011, 11, 210–222.

17. Inagaki, N.; Seino, Y.; Takeda, J.; Yano, H.; Yamada, Y.; Bell, G.I.; Eddy, R.L.; Fukushima, Y.; Byers, M.G.; Shows, T.B.; et al. Gastric inhibitory polypeptide: Structure and chromosomal localization of the human gene. Mol. Endocrinol. 1989, 3, 1014–1021.

18. Tseng, C.C.; Jarboe, L.A.; Landau, S.B.; Williams, E.K.; Wolfe, M.M. Glucose-dependent insulinotropic peptide: Structure of the precursor and tissue-specific expression in rat. Proc. Natl. Acad. Sci. USA 1993, 90, 1992–1996.

19. Ojima, A.; Matsui, T.; Maeda, S.; Takeuchi, M.; Yamagishi, S. Glucose-dependent insulinotropic polypeptide (gip) inhibits signaling pathways of advanced glycation end products (ages) in endothelial cells via its antioxidative properties. Horm. Metab. Res. 2012, 44, 501–505.

20. Harada, N. Structure and function of incretin receptor. Nihon Rinsho 2011, 69, 813–820. (in Japanese)
21. Yamada, Y.; Hayami, T.; Nakamura, K.; Kaisaki, P.J.; Someya, Y.; Wang, C.Z.; Seino, S.; Seino, Y. Human gastric inhibitory polypeptide receptor: Cloning of the gene (gipr) and cdna. *Genomics* **1995**, *29*, 773–776.

22. Gremlich, S.; Porret, A.; Hani, E.H.; Cherif, D.; Vionnet, N.; Froguel, P.; Thorens, B. Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulino tropic polypeptide receptor. *Diabetes* **1995**, *44*, 1202–1208.

23. Hauner, H.; Glatting, G.; Kaminska, D.; Pfieffer, E.F. Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes. *Ann. Nutr. Metab.* **1988**, *32*, 282–288.

24. Kogire, M.; Inoue, K.; Sumi, S.; Doi, R.; Yun, M.; Kaji, H.; Tobe, T. Effects of gastric inhibitory polypeptide and glucagon on portal venous and hepatic arterial flow in conscious dogs. *Digest. Dis. Sci.* **1992**, *37*, 1666–1670.

25. Holst, J.J. On the physiology of gip and glp-1. *Horm. Metab. Res.* **2004**, *36*, 747–754.

26. Hansotia, T.; Drucker, D.J. Gip and glp-1 as incretin hormones: Lessons from single and double incretin receptor knockout mice. *Regul. Pept.* **2005**, *128*, 125–134.

27. Gault, V.A.; Harriott, P.; Flatt, P.R.; O’Harte, F.P. Cyclic amp production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulino tropic polypeptide. *Biosci. Rep.* **2002**, *22*, 523–528.

28. Ehses, J.A.; Lee, S.S.; Pederson, R.A.; McIntosh, C.H. A new pathway for glucose-dependent insulino tropic polypeptide (gip) receptor signaling: Evidence for the involvement of phospholipase a2 in gip-stimulated insulin secretion. *J. Biol. Chem.* **2001**, *276*, 23667–23673.

29. Volz, A.; Goke, R.; Lankat-Buttgereit, B.; Fehmann, H.C.; Bode, H.P.; Goke, B. Molecular cloning, functional expression, and signal transduction of the gip-receptor cloned from a human insulinoma. *FEBS Lett.* **1995**, *373*, 23–29.

30. Brubaker, P.L.; Drucker, D.J. Structure-function of the glucagon receptor family of g protein-coupled receptors: The glucagon, gip, glp-1, and glp-2 receptors. *Recept. Channels* **2002**, *8*, 179–188.

31. Kaplan, A.M.; Vigna, S.R. Gastric inhibitory polypeptide (gip) binding sites in rat brain. *Peptides* **1994**, *15*, 297–302.

32. Gault, V.A.; Holscher, C. Protease-resistant glucose-dependent insulino tropic polypeptide agonists facilitate hippocampal ltp and reverse the impairment of ltp induced by beta-amyloid. *J. Neurophysiol.* **2008**, *99*, 1590–1595.

33. Figueiredo, C.P.; Pamplona, F.A.; Mazzuco, T.L.; Aguiar, A.S., Jr.; Walz, R.; Prediger, R.D. Role of the glucose-dependent insulino tropic polypeptide and its receptor in the central nervous system: Therapeutic potential in neurological diseases. *Behav. Pharmacol.* **2010**, *21*, 394–408.

34. Faivre, E.; Gault, V.A.; Thorens, B.; Holscher, C. Glucose-dependent insulino tropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis. *J. Neurophysiol.* **2011**, *105*, 1574–1580.

35. Buhren, B.A.; Gasis, M.; Thorens, B.; Muller, H.W.; Bosse, F. Glucose-dependent insulino tropic polypeptide (gip) and its receptor (gipr): Cellular localization, lesion-affected expression, and impaired regenerative axonal growth. *J. Neurosci. Res.* **2009**, *87*, 1858–1870.
36. Nyberg, J.; Jacobsson, C.; Anderson, M.F.; Eriksson, P.S. Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain. *J. Neurosci. Res.* 2007, 85, 2099–2119.

37. Nyberg, J.; Anderson, M.F.; Meister, B.; Alborn, A.M.; Strom, A.K.; Brederlau, A.; Illerskog, A.C.; Nilsson, O.; Kieffer, T.J.; Hietala, M.A.; *et al.* Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. *J. Neurosci.* 2005, 25, 1816–1825.

38. Kim, S.J.; Ao, Z.; Warnock, G.; McIntosh, C.H. Incretin-stimulated interaction between beta-cell kv1.5 and kvlbeta2 channel proteins involves acetylation/deacetylation by cbp/sirt1. *Biochem. J.* 2013, 451, 227–234.

39. Yabe, D.; Seino, Y. Two incretin hormones glp-1 and gip: Comparison of their actions in insulin secretion and beta cell preservation. *Prog. Biophys. Mol. Biol.* 2011, 107, 248–256.

40. Campbell, R.K. Fate of the beta-cell in the pathophysiology of type 2 diabetes. *J. Am. Pharm. Assoc.* 2009, 49, S10–S15.

41. Maida, A.; Hansotia, T.; Longuet, C.; Seino, Y.; Drucker, D.J. Differential importance of glucose-dependent insulinotropic polypeptide vs. glucagon-like peptide 1 receptor signaling for beta cell survival in mice. *Gastroenterology* 2009, 137, 2146–2157.

42. Widenmaier, S.B.; Ao, Z.; Kim, S.J.; Warnock, G.; McIntosh, C.H. Suppression of p38 mapk and jnk via akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide. *J. Biol. Chem.* 2009, 284, 30372–30382.

43. Kim, S.J.; Nian, C.; Widenmaier, S.; McIntosh, C.H. Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic bel-2 gene expression is coordinated by cyclic amp (camp) response element binding protein (creb) and camp-responsive creb coactivator 2. *Mol. Cell. Biol.* 2008, 28, 1644–1656.

44. Trumper, A.; Trumper, K.; Horsch, D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(ins-1)-cells. *J. Endocrinol.* 2002, 174, 233–246.

45. Kim, S.J.; Winter, K.; Nian, C.; Tsuneoka, M.; Koda, Y.; McIntosh, C.H. Glucose-dependent insulinotropic polypeptide (gip) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (pi3k)/protein kinase b (pkb) signaling, inactivation of the forkhead transcription factor foxo1, and down-regulation of bax expression. *J. Biol. Chem.* 2005, 280, 22297–22307.

46. Lyssenko, V.; Eliasson, L.; Kotova, O.; Pilgaard, K.; Wierup, N.; Salehi, A.; Wendt, A.; Jonsson, A.; de Marinis, Y.Z.; Berglund, L.M.; *et al.* Pleiotropic effects of gip on islet function involve osteopontin. *Diabetes* 2011, 60, 2424–2433.

47. Tsukiyama, K.; Yamada, Y.; Yamada, C.; Harada, N.; Kawasaki, Y.; Ogura, M.; Bessho, K.; Li, M.; Amizuka, N.; Sato, M.; *et al.* Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. *Mol. Endocrinol.* 2006, 20, 1644–1651.

48. Kubota, A.; Yamada, Y.; Yasuda, K.; Someya, Y.; Ihara, Y.; Kagimoto, S.; Watanabe, R.; Kuroe, A.; Ishida, H.; Seino, Y. Gastric inhibitory polypeptide activates map kinase through the wortmannin-sensitive and -insensitive pathways. *Biochem. Biophys. Res. Commun.* 1997, 235, 171–175.
49. Ehses, J.A.; Casilla, V.R.; Doty, T.; Pospisilik, J.A.; Winter, K.D.; Demuth, H.U.; Pederson, R.A.; McIntosh, C.H. Glucose-dependent insulinotropic polypeptide promotes beta-(ins-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. *Endocrinology* **2003**, *144*, 4433–4445.

50. Yasuda, K.; Inagaki, N.; Yamada, Y.; Kubota, A.; Seino, S.; Seino, Y. Hamster gastric inhibitory polypeptide receptor expressed in pancreatic islets and clonal insulin-secreting cells: Its structure and functional properties. *Biochem. Biophys. Res. Commun.* **1994**, *205*, 1556–1562.

51. Zeng, X.J.; Yu, S.P.; Zhang, L.; Wei, L. Neuroprotective effect of the endogenous neural peptide apelin in cultured mouse cortical neurons. *Exp. Cell Res.* **2010**, *316*, 1773–1783.

52. O’Donnell, L.A.; Agrawal, A.; Sabnekar, P.; Dichter, M.A.; Lynch, D.R.; Kolson, D.L. Apelin, an endogenous neuronal peptide, protects hippocampal neurons against excitotoxic injury. *J. Neurochem.* **2007**, *102*, 1905–1917.

53. Reaux, A.; de Mota, N.; Skultetyova, I.; Lenkei, Z.; El Messari, S.; Gallatz, K.; Corvol, P.; Palkovits, M.; Llorens-Cortes, C. Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. *J. Neurochem.* **2001**, *77*, 1085–1096.

54. Cook, D.R.; Gleichman, A.J.; Cross, S.A.; Doshi, S.; Ho, W.; Jordan-Sciutto, K.L.; Lynch, D.R.; Kolson, D.L. Nmda receptor modulation by the neuropeptide apelin: Implications for excitotoxic injury. *J. Neurochem.* **2011**, *118*, 1113–1123.

55. Kasai, A.; Kinjo, T.; Ishihara, R.; Sakai, I.; Ishimaru, Y.; Yoshioka, Y.; Yamamuro, A.; Ishige, K.; Ito, Y.; Maeda, S. Apelin deficiency accelerates the progression of amyotrophic lateral sclerosis. *PLoS One* **2011**, *6*, e23968.

56. Morganti, J.M.; Nash, K.R.; Grimmig, B.A.; Ranjit, S.; Small, B.; Bickford, P.C.; Gemma, C. The soluble isoform of cx3cl1 is necessary for neuroprotection in a mouse model of parkinson’s disease. *J. Neurosci.* **2012**, *32*, 14592–14601.

57. Hao, F.; Zhang, N.N.; Zhang, D.M.; Bai, H.Y.; Piao, H.; Yuan, B.; Zhu, H.Y.; Yu, H.; Xiao, C.S.; Li, A.P. Chemokine fractalkine attenuates overactivation and apoptosis of bv-2 microglial cells induced by extracellular atp. *Neurochem. Res.* **2013**, *38*, 1002–1012.

58. Cipriani, R.; Villà, P.; Cheche, G.; Lauro, C.; Paladini, A.; Micotti, E.; Perego, C.; de Simoni, M.G.; Fredholm, B.B.; Eusebi, F.; et al. Cx3cl1 is neuroprotective in permanent focal cerebral ischemia in rodents. *J. Neurosci.* **2011**, *31*, 16327–16335.

59. Lauro, C.; Cipriani, R.; Catalano, M.; Trettel, F.; Cheche, G.; Brusadin, V.; Antonilli, L.; van Rooijen, N.; Eusebi, F.; Fredholm, B.B.; et al. Adenosine a1 receptors and microglial cells mediate cx3cl1-induced protection of hippocampal neurons against glu-induced death. *Neuropsychopharmacology* **2010**, *35*, 1550–1559.

60. Noda, M.; Doi, Y.; Liang, J.; Kawanokuchi, J.; Sonobe, Y.; Takeuchi, H.; Mizuno, T.; Suzumura, A. Fractalkine attenuates excito-neurotoxicity via microglial clearance of damaged neurons and antioxidant enzyme heme oxyge-nase-1 expression. *J. Biol. Chem.* **2011**, *286*, 2308–2319.

61. Boehme, S.A.; Lio, F.M.; Maciejewski-Lenoir, D.; Bacon, K.B.; Conlon, P.J. The chemokine fractalkine inhibits fas-mediated cell death of brain microglia. *J. Immunol.* **2000**, *165*, 397–403.

62. Cook, A.; Hippensteel, R.; Shimizu, S.; Nicolai, J.; Fatatis, A.; Meucci, O. Interactions between chemokines: Regulation of fractalkine/cx3cl1 homeostasis by sdf/cxcl12 in cortical neurons. *J. Biol. Chem.* **2010**, *285*, 10563–10571.
63. Catalano, M.; Lauro, C.; Cipriani, R.; Chege, G.; Ponzetta, A.; di Angelantonio, S.; Ragozzino, D.; Limatola, C. Cx3cl1 protects neurons against excitotoxicity enhancing glt-1 activity on astrocytes. *J. Neuroimmunol.* 2013, 263, 75–82.

64. Yuan, Q.; Chiquet, B.T.; Devault, L.; Warman, M.L.; Nakamura, Y.; Swindell, E.C.; Hecht, J.T. Craniofacial abnormalities result from knock down of nonsyndromic clefting gene, *crispld2*, in zebrafish. *Genesis* 2012, 50, 871–881.

65. Szlama, G.; Kondas, K.; Trexler, M.; Patthy, L. Wfikkn1 and wfikkn2 bind growth factors tgfbeta1, bmp2 and bmp4 but do not inhibit their signalling activity. *FEBS J.* 2010, 277, 5040–5050.

66. Liu, Y.; Cheng, H.; Zhou, Y.; Zhu, Y.; Bian, R.; Chen, Y.; Li, C.; Ma, Q.; Zheng, Q.; Zhang, Y.; *et al.* Myostatin induces mitochondrial metabolic alteration and typical apoptosis in cancer cells. *Cell Death Dis.* 2013, 4, e494.

67. Holzbaur, E.L.; Howland, D.S.; Weber, N.; Wallace, K.; She, Y.; Kwak, S.; Tchistiakova, L.A.; Murphy, E.; Hinson, J.; Karim, R.; *et al.* Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. *Neurobiol. Dis.* 2006, 23, 697–707.

68. Filipe, M.; Goncalves, L.; Bento, M.; Silva, A.C.; Belo, J.A. Comparative expression of mouse and chicken shisa homologues during early development. *Dev. Dyn.* 2006, 235, 2567–2573.

69. Pei, J.; Grishin, N.V. Unexpected diversity in shisa-like proteins suggests the importance of their roles as transmembrane adaptors. *Cell Signal.* 2012, 24, 758–769.

70. Schultze, W.; Eulenburg, V.; Lessmann, V.; Herrmann, L.; Dittmar, T.; Gundelfinger, E.D.; Heumann, R.; Erdmann, K.S. Semaphorin4f interacts with the synapse-associated protein sap90/psd-95. *J. Neurochem.* 2001, 78, 482–489.

71. Barrette, B.; Calvo, E.; Vallieres, N.; Lacroix, S. Transcriptional profiling of the injured sciatic nerve of mice carrying the *Wld*(s) mutant gene: Identification of genes involved in neuroprotection, neuroinflammation, and nerve regeneration. *Brain Behav. Immun.* 2010, 24, 1254–1267.

72. Li, T.S.; Li, X.N.; Chang, Z.J.; Fu, X.Y.; Liu, L. Identification and functional characterization of a novel interleukin 17 receptor: A possible mitogenic activation through ras/mitogen-activated protein kinase signaling pathway. *Cell Signal.* 2006, 18, 1287–1298.

73. Moseley, T.A.; Haudenschild, D.R.; Rose, L.; Reddi, A.H. Interleukin-17 family and il-17 receptors. *Cytokine Growth Factor Rev.* 2003, 14, 155–174.

74. Vidlak, D.; Kielian, T. Differential effects of interleukin-17 receptor signaling on innate and adaptive immunity during central nervous system bacterial infection. *J. Neuroinflam.* 2012, 9, 128.

75. Bonni, A.; Brunet, A.; West, A.E.; Datta, S.R.; Takasu, M.A.; Greenberg, M.E. Cell survival promoted by the ras-mapk signaling pathway by transcription-dependent and independent mechanisms. *Science* 1999, 286, 1358–1362.

76. Holt, E.H.; Broadus, A.E.; Brines, M.L. Parathyroid hormone-related peptide is produced by cultured cerebellar granule cells in response to l-type voltage-sensitive Ca$^{2+}$ channel flux via a Ca$^{2+}$/calmodulin-dependent kinase pathway. *J. Biol. Chem.* 1996, 271, 28105–28111.

77. Ono, T.; Inokuchi, K.; Ogura, A.; Ikawa, Y.; Kudo, Y.; Kawashima, S. Activity-dependent expression of parathyroid hormone-related protein (pthrp) in rat cerebellar granule neurons. Requirement of pthrp for the activity-dependent survival of granule neurons. *J. Biol. Chem.* 1997, 272, 14404–14411.
87. Fatemi, S.H.; King, D.P.; Reutiman, T.J.; Folsom, T.D.; Laurence, J.A.; Lee, S.; Fan, Y.T.; Paciga, S.A.; Conti, M.; Menniti, F.S. Pde4b polymorphisms and decreased pde4b expression are associated with schizophrenia. Schizophr. Res. 2008, 101, 36–49.

88. Zeng, W.; Kong, Q.; Li, C.; Mao, B. Xenopus rcor2 (rest corepressor 2) interacts with zmynd8, which is involved in neural differentiation. Biochem. Biophys. Res. Commun. 2010, 394, 1024–1029.

89. Lee, S.H.; Chen, T.; Zhou, J.; Hofmann, J.; Bepler, G. Protein kinase c-beta gene variants, pathway activation, and enzastaurin activity in lung cancer. Clin. Lung Cancer 2010, 11, 169–175.

90. Lim, S.; Naisbitt, S.; Yoon, J.; Hwang, J.I.; Suh, P.G.; Sheng, M.; Kim, E. Characterization of the Shank family of synaptic proteins. Multiple genes, alternative splicing, and differential expression in brain and development. J. Biol. Chem. 1999, 274, 29510–29518.

91. Boeckers, T.M.; Bockmann, J.; Kreutz, M.R.; Gundelfinger, E.D. Prosap/shank proteins—A family of higher order organizing molecules of the postsynaptic density with an emerging role in human neurological disease. J. Neurochem. 2002, 81, 903–910.
92. Park, E.; Na, M.; Choi, J.; Kim, S.; Lee, J.R.; Yoon, J.; Park, D.; Sheng, M.; Kim, E. The Shank family of postsynaptic density proteins interacts with and promotes synaptic accumulation of the beta pix guanine nucleotide exchange factor for Rac1 and cdc42. *J. Biol. Chem.* 2003, 278, 19220–19229.

93. Naisbitt, S.; Kim, E.; Weinberg, R.J.; Rao, A.; Yang, F.C.; Craig, A.M.; Sheng, M. Characterization of guanylate kinase-associated protein, a postsynaptic density protein at excitatory synapses that interacts directly with postsynaptic density-95/synapse-associated protein 90. *J. Neurosci.* 1997, 17, 5687–5696.

94. Boeckers, T.M.; Winter, C.; Smalla, K.H.; Kreutz, M.R.; Bockmann, J.; Seidenbecher, C.; Garner, C.C.; Gundelfinger, E.D. Proline-rich synapse-associated proteins prosap1 and prosap2 interact with synaptic proteins of the Sapap/Gkap family. *Biochem. Biophys. Res. Commun.* 1999, 264, 247–252.

95. Moutin, E.; Raynaud, F.; Fagni, L.; Perroy, J. Gkap-dlc2 interaction organizes the postsynaptic scaffold complex to enhance synaptic NMDA receptor activity. *J. Cell Sci.* 2012, 125, 2030–2040.

96. Grabrucker, A.M. A role for synaptic zinc in prosap/shank PSD scaffold malformation in autism spectrum disorders. *Dev. Neurobiol.* 2014, 74, 136–146.

97. Li, J.M.; Lu, C.L.; Cheng, M.C.; Luu, S.U.; Hsu, S.H.; Chen, C.H. Genetic analysis of the dlgap1 gene as a candidate gene for schizophrenia. *Psychiatry Res.* 2013, 205, 13–17.

98. Liu, C.; Lin, C.; Whitaker, D.T.; Bakeri, H.; Bulgakov, O.V.; Liu, P.; Lei, J.; Dong, L.; Li, T.; Swaroop, A. Prickle1 is expressed in distinct cell populations of the central nervous system and contributes to neuronal morphogenesis. *Hum. Mol. Genet.* 2013, 22, 2234–2246.

99. Fujimura, L.; Hatano, M. Role of prickle1 and prickle2 in neurite outgrowth in murine neuroblastoma cells. *Methods Mol. Biol.* 2012, 839, 173–185.

100. Fujimura, L.; Watanabe-Takano, H.; Sato, Y.; Tokuhisa, T.; Hatano, M. Prickle promotes neurite outgrowth via the dishevelled dependent pathway in c1300 cells. *Neurosci. Lett.* 2009, 467, 6–10.

101. Bassuk, A.G.; Wallace, R.H.; Buhr, A.; Buller, A.R.; Afawi, Z.; Shimojo, M.; Miyata, S.; Chen, S.; Gonzalez-Alegre, P.; Griesbach, H.L.; et al. A homozygous mutation in human prickle1 causes an autosomal-recessive progressive myoclonus epilepsy-ataxia syndrome. *Am. J. Hum. Genet.* 2008, 83, 572–581.

102. Toyoshima, Y.; Karas, M.; Yakar, S.; Dupont, J.; Lee, H.; LeRoith, D. Tdag51 mediates the effects of insulin-like growth factor i (igf-i) on cell survival. *J. Biol. Chem.* 2004, 279, 25898–25904.

103. Murata, T.; Sato, T.; Kamoda, T.; Moriya, H.; Kumazawa, Y.; Hanada, N. Differential susceptibility to hydrogen sulfide-induced apoptosis between phlda1-overexpressing oral cancer cell lines and oral keratinocytes: Role of phlda1 as an apoptosis suppressor. *Exp. Cell Res.* 2014, 320, 247–257.

104. Park, E.S.; Kim, J.; Ha, T.U.; Choi, J.S.; Soo Hong, K.; Rho, J. Tdag51 deficiency promotes oxidative stress-induced apoptosis through the generation of reactive oxygen species in mouse embryonic fibroblasts. *Exp. Mol. Med.* 2013, 45, e35.

105. Xi, Z.Q.; Wang, L.Y.; Sun, J.J.; Liu, X.Z.; Zhu, X.; Xiao, F.; Guan, L.F.; Li, J.M.; Wang, L.; Wang, X.F. Tdag51 in the anterior temporal neocortex of patients with intractable epilepsy. *Neurosci. Lett.* 2007, 425, 53–58.
106. Van Wayenbergh, R.; Taelman, V.; Pichon, B.; Fischer, A.; Kricha, S.; Gessler, M.; Christophe, D.; Bellefroid, E.J. Identification of boip, a novel cdna highly expressed during spermatogenesis that encodes a protein interacting with the orange domain of the hairy-related transcription factor hrt1/hey1 in xenopus and mouse. Dev. Dyn. 2003, 228, 716–725.

107. Jacot, T.A.; Zalenskaya, I.; Mauck, C.; Archer, D.F.; Doneel, G.F. Tspy4 is a novel sperm-specific biomarker of semen exposure in human cervicovaginal fluids; potential use in hiv prevention and contraception studies. Contraception 2013, 88, 387–395.

108. Kido, T.; Schubert, S.; Schmidtke, J.; Chris Lau, Y.F. Expression of the human tspy gene in the brains of transgenic mice suggests a potential role of this y chromosome gene in neural functions. Yi Chuan Xue Bao 2011, 38, 181–191. (in Chinese)

109. Williams, M.; Lyu, M.S.; Yang, Y.L.; Lin, E.P.; Dunbrack, R.; Birren, B.; Cunningham, J.; Hunter, K. Ier5, a novel member of the slow-kinetics immediate-early genes. Genomics 1999, 55, 327–334.

110. Cirelli, C.; Tononi, G. Gene expression in the brain across the sleep-waking cycle. Brain Res. 2000, 885, 303–321.

111. Baye, T.M.; Wilke, R.A.; Olivier, M. Genomic and geographic distribution of private snps and pathways in human populations. Personal. Med. 2009, 6, 623–641.

112. Konishi, Y.; Aoki, T.; Ohkawa, N.; Matsu-Ura, T.; Mikoshiba, K.; Tamura, T. Identification of the C-terminal activation domain of the neurod-related factor (ndrf). Nucleic Acids Res. 2000, 28, 2406–2412.

113. Bormuth, I.; Yan, K.; Yonematsu, T.; Gummert, M.; Zhang, M.; Wichert, S.; Grishina, O.; Pieper, A.; Zhang, W.; Goebbels, S.; et al. Neuronal basic helix-loop-helix proteins neurod2/6 regulate cortical commissure formation before midline interactions. J. Neurosci. 2013, 33, 641–651.

114. Schwab, M.H.; Bartholomae, A.; Heimrich, B.; Feldmeyer, D.; Druffel-Augustin, S.; Goebbels, S.; Naya, F.J.; Zhao, S.; Frotscher, M.; Tsai, M.J.; et al. Neuronal basic helix-loop-helix proteins (nex and beta2/neuro d) regulate terminal granule cell differentiation in the hippocampus. J. Neurosci. 2000, 20, 3714–3724.

115. Konishi, Y.; Matsu-ura, T.; Mikoshiba, K.; Tamura, T. Stimulation of gene expression of neurod-related factor in the mouse brain following pentylenetetrazol-induced seizures. Brain Res. 2001, 97, 129–136.

116. Lin, C.H.; Hansen, S.; Wang, Z.; Storm, D.R.; Tapscott, S.J.; Olson, J.M. The dosage of the neurod2 transcription factor regulates amygdala development and emotional learning. Proc. Natl. Acad. Sci. USA 2005, 102, 14877–14882.

117. Lin, C.H.; Stoeck, J.; Ravanpay, A.C.; Guillemot, F.; Tapscott, S.J.; Olson, J.M. Regulation of neurod2 expression in mouse brain. Dev. Biol. 2004, 265, 234–245.

118. Olson, J.M.; Asakura, A.; Snider, L.; Hawkes, R.; Strand, A.; Stoeck, J.; Hallahan, A.; Pritchard, J.; Tapscott, S.J. Neurod2 is necessary for development and survival of central nervous system neurons. Dev. Biol. 2001, 234, 174–187.

119. Flames, N.; Hobert, O. Gene regulatory logic of dopamine neuron differentiation. Nature 2009, 458, 885–889.

120. Abe, H.; Okazawa, M.; Nakanishi, S. The etv1/er81 transcription factor orchestrates activity-dependent gene regulation in the terminal maturation program of cerebellar granule cells. Proc. Natl. Acad. Sci. USA 2011, 108, 12497–12502.
121. Abe, H.; Okazawa, M.; Nakanishi, S. Gene regulation via excitation and bdnf is mediated by induction and phosphorylation of the etv1 transcription factor in cerebellar granule cells. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 8734–8739.

122. Tuoc, T.C.; Stoykova, A. Er81 is a downstream target of pax6 in cortical progenitors. *BMC Dev. Biol.* **2008**, *8*, 23.

123. Arber, S.; Ladle, D.R.; Lin, J.H.; Frank, E.; Jessell, T.M. Ets gene er81 controls the formation of functional connections between group ia sensory afferents and motor neurons. *Cell* **2000**, *101*, 485–498.

124. Zhang, Z.; Pinto, A.M.; Wan, L.; Wang, W.; Berg, M.G.; Oliva, I.; Singh, L.N.; Dengler, C.; Wei, Z.; Dreyfuss, G. Dysregulation of synaptogenesis genes antecedes motor neuron pathology in spinal muscular atrophy. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 19348–19353.

125. Chen, Y.; Zou, H.; Yang, L.Y.; Li, Y.; Wang, L.; Hao, Y.; Yang, J.L. Er81-shrna inhibits growth of triple-negative human breast cancer cell line mda-mb-231 in vivo and in vitro. *Asian Pac. J. Cancer Prev.* **2012**, *13*, 2385–2392.

126. Scheer, E.; Delbac, F.; Tora, L.; Moras, D.; Romier, C. Tfiid taf6–taf9 complex formation involves the heat repeat-containing C-terminal domain of taf6 and is modulated by taf5 protein. *J. Biol. Chem.* **2012**, *287*, 27580–27592.

127. Wilhelm, E.; Kornete, M.; Targat, B.; Vigneault-Edwards, J.; Frontini, M.; Tora, L.; Benecke, A.; Bell, B. Taf6delta orchestrates an apoptotic transcriptome profile and interacts functionally with p53. *BMC Mol. Biol.* **2010**, *11*, 10.

128. Mizuta, T.R.; Fukita, Y.; Miyoshi, T.; Shimizu, A.; Honjo, T. Isolation of cdna encoding a binding protein specific to 5'-phosphorylated single-stranded DNA with g-rich sequences. *Nucleic Acids Res.* **1993**, *21*, 1761–1766.

129. Krieger, F.; Elflein, N.; Ruiz, R.; Guerra, J.; Serrano, A.L.; Asan, E.; Tabares, L.; Jablonka, S. Fast motor axon loss in smard1 does not correspond to morphological and functional alterations of the NMJ. *Neurobiol. Dis.* **2013**, *54*, 169–182.

130. Tachi, N.; Kikuchi, S.; Kozuka, N.; Nogami, A. A new mutation of ighmbp2 gene in spinal muscular atrophy with respiratory distress type 1. *Pediatr. Neurol.* **2005**, *32*, 288–290.

131. Kulemzina, I.; Schumacher, M.R.; Verma, V.; Reiter, J.; Metzler, J.; Failla, A.V.; Lanz, C.; Sreedharan, V.T.; Ratsch, G.; Ivanov, D. Cohesin rings devoid of scc3 and pds5 maintain their stable association with the DNA. *PLoS Genet.* **2012**, *8*, e1002856.

132. Chan, K.L.; Gilgoris, T.; Upcher, W.; Kato, Y.; Shirahige, K.; Nasmyth, K.; Beckouet, F. Pds5 promotes and protects cohesin acetylation. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 13020–13025.

133. Ren, Q.; Yang, H.; Rosinski, M.; Conrad, M.N.; Dresser, M.E.; Guacci, V.; Zhang, Z. Mutation of the cohesin related gene pds5 causes cell death with predominant apoptotic features in *saccharomyces cerevisiae* during early meiosis. *Mutat. Res.* **2005**, *570*, 163–173.
136. Zhang, B.; Chang, J.; Fu, M.; Huang, J.; Kashyap, R.; Salavaggione, E.; Jain, S.; Kulkarni, S.; Deardorff, M.A.; Uzielli, M.L.; et al. Dosage effects of cohesin regulatory factor pds5 on mammalian development: Implications for cohesinopathies. *PLoS One* 2009, 4, e5232.
137. Hur, S.K.; Park, E.J.; Han, J.E.; Kim, Y.A.; Kim, J.D.; Kang, D.; Kwon, J. Roles of human ino80 chromatin remodeling enzyme in DNA replication and chromosome segregation suppress genome instability. *Cell. Mol. Life Sci.* 2010, 67, 2283–2296.
138. Seeber, A.; Dion, V.; Gasser, S.M. Checkpoint kinases and the ino80 nucleosome remodeling complex enhance global chromatin mobility in response to DNA damage. *Genes Dev.* 2013, 27, 1999–2008.
139. Park, E.J.; Hur, S.K.; Kwon, J. Human ino80 chromatin-remodelling complex contributes to DNA double-strand break repair via the expression of rad54b and xrcc3 genes. *Biochem. J.* 2010, 431, 179–187.
140. Fischle, W.; Franz, H.; Jacobs, S.A.; Allis, C.D.; Khorasanizadeh, S. Specificity of the chromodomain y chromosome family of chromodomains for lysine-methylated ark(s/t) motifs. *J. Biol. Chem.* 2008, 283, 19626–19635.
141. Gu, P.; Min, J.N.; Wang, Y.; Huang, C.; Peng, T.; Chai, W.; Chang, S. Ctc1 deletion results in defective telomere replication, leading to catastrophic telomere loss and stem cell exhaustion. *EMBO J.* 2012, 31, 2309–2321.
142. Chen, L.Y.; Redon, S.; Lingner, J. The human cst complex is a terminator of telomerase activity. *Nature* 2012, 488, 540–544.
143. Kasbek, C.; Wang, F.; Price, C.M. Human ten1 maintains telomere integrity and functions in genome-wide replication restart. *J. Biol. Chem.* 2013, 288, 30139–30150.
144. Gramatges, M.M.; Bertuch, A.A. Short telomeres: From dyskeratosis congenita to sporadic aplastic anemia and malignancy. *Transl. Res.* 2013, 162, 353–363.
145. Lee, K.D.; Pai, M.Y.; Hsu, C.C.; Chen, C.C.; Chen, Y.L.; Chu, P.Y.; Lee, C.H.; Chen, L.T.; Chang, J.Y.; Huang, T.H.; et al. Targeted casp8ap2 methylation increases drug resistance in mesenchymal stem cells and cancer cells. *Biochem. Biophys. Res. Commun.* 2012, 422, 578–585.
146. Kumral, A.; Tuzun, F.; Tugyan, K.; Ozbal, S.; Yilmaz, O.; Yesilirmak, C.D.; Duman, N.; Ozkan, H. Role of epigenetic regulatory mechanisms in neonatal hypoxic-ischemic brain injury. *Early Hum. Dev.* 2013, 89, 165–173.
147. Imai, Y.; Kimura, T.; Murakami, A.; Yajima, N.; Sakamaki, K.; Yonehara, S. The ced-4-homologous protein flash is involved in fas-mediated activation of caspase-8 during apoptosis. *Nature* 1999, 398, 777–785.
148. Yang, X.C.; Burch, B.D.; Yan, Y.; Marzluff, W.F.; Dominski, Z. Flash, a proapoptotic protein involved in activation of caspase-8, is essential for 3' end processing of histone pre-mrnas. *Mol. Cell* 2009, 36, 267–278.
149. Burmester, T.; Ebner, B.; Weich, B.; Hankeln, T. Cytoglobin: A novel globin type ubiquitously expressed in vertebrate tissues. *Mol. Biol. Evolut.* 2002, 19, 416–421.
150. Ascenzi, P.; Marino, M.; Polticelli, F.; Coletta, M.; Gioia, M.; Marini, S.; Pesce, A.; Nardini, M.; Bolognesi, M.; Reeder, B.J.; et al. Non-covalent and covalent modifications modulate the reactivity of monomeric mammalian globins. *Biochim. Biophys. Acta* 2013, 1834, 1750–1756.
151. Tian, S.F.; Yang, H.H.; Xiao, D.P.; Huang, Y.J.; He, G.Y.; Ma, H.R.; Xia, F.; Shi, X.C. Mechanisms of neuroprotection from hypoxia-ischemia (hi) brain injury by up-regulation of cytoglobin (cygb) in a neonatal rat model. *J. Biol. Chem.* 2013, 288, 15988–16003.

152. Hundahl, C.A.; Elfving, B.; Muller, H.K.; Hay-Schmidt, A.; Wegener, G. A gene-environment study of cytoglobin in the human and rat hippocampus. *PLoS One* 2013, 8, e63288.

153. Beltran-Parrazal, L.; Acuna, D.; Ngan, A.M.; Kim, E.; Ngan, A.; Kawakami, K.; Edmond, J.; Lopez, I.A. Neuroglobin, cytoglobin, and transcriptional profiling of hypoxia-related genes in the rat cerebellum after prenatal chronic very mild carbon monoxide exposure (25 ppm). *Brain Res.* 2010, 1330, 61–71.

154. Araki, T.; Milbrandt, J. Znrf proteins constitute a family of presynaptic e3 ubiquitin ligases. *J. Neurosci.* 2003, 23, 9385–9394.

155. Yoshida, K.; Watanabe, M.; Hatakeyama, S. Znrf1 interacts with tubulin and regulates cell morphogenesis. *Biochem. Biophys. Res. Commun.* 2009, 389, 506–511.

156. Saitoh, F.; Araki, T. Proteasomal degradation of glutamine synthetase regulates schwann cell differentiation. *J. Neurosci.* 2010, 30, 1204–1212.

157. Tidd, D.M.; Broughton, C.M.; Clark, R.E. Cpg oligodeoxynucleotide 5mer-induced apoptosis in mol–4 leukaemia cells does not require caspase 3 or new protein synthesis. *Nucleic Acids Res.* 2003, 31, 2297–2304.

158. Matsuki, H.; Takahashi, M.; Higuchi, M.; Makokha, G.N.; Oie, M.; Fujii, M. Both g3bp1 and g3bp2 contribute to stress granule formation. *Genes Cells* 2013, 18, 135–146.

159. Takahashi, M.; Higuchi, M.; Matsuki, H.; Yoshita, M.; Ohsawa, T.; Oie, M.; Fujii, M. Stress granules inhibit apoptosis by reducing reactive oxygen species production. *Mol. Cell. Biol.* 2013, 33, 815–829.

160. Maretzky, T.; McIlwain, D.R.; Issuree, P.D.; Li, X.; Malapeira, J.; Amin, S.; Lang, P.A.; Mak, T.W.; Blobel, C.P. Irhom2 controls the substrate selectivity of stimulated adam17-dependent ectodomain shedding. *Proc. Natl. Acad. Sci. USA* 2013, 110, 11433–11438.

161. Christova, Y.; Adrain, C.; Bambrough, P.; Ibrahim, A.; Freeman, M. Mammalian irhoms have distinct physiological functions including an essential role in tace regulation. *EMBO Rep.* 2013, 14, 884–890.

162. Hurtado, O.; Lizasoain, I.; Fernandez-Tome, P.; Alvarez-Barrientos, A.; Leza, J.C.; Lorenzo, P.; Moro, M.A. Tace/adam17-tnf-alpha pathway in rat cortical cultures after exposure to oxygen-glucose deprivation or glutamate. *J. Cereb. Blood Flow Metab.* 2002, 22, 576–585.

163. Meliopoulos, V.A.; Andersen, L.E.; Brooks, P.; Yan, X.; Bakre, A.; Coleman, J.K.; Tompkins, S.M.; Tripp, R.A. Microrna regulation of human protease genes essential for influenza virus replication. *PLoS One* 2012, 7, e37169.

164. Liu, Y.; Kern, J.T.; Walker, J.R.; Johnson, J.A.; Schultz, P.G.; Luesch, H. A genomic screen for activators of the antioxidant response element. *Proc. Natl. Acad. Sci. USA* 2007, 104, 5205–5210.

165. Staneviciene, I.; Sadauskiene, I.; Lesauskaite, V.; Ivanoviene, L.; Kasauskas, A.; Ivanov, L. Subacute effects of cadmium and zinc ions on protein synthesis and cell death in mouse liver. *Medicina* 2008, 44, 131–138.

166. Munakata, K.; Iwamoto, K.; Bundo, M.; Kato, T. Mitochondrial DNA 3243A > G mutation and increased expression of lars2 gene in the brains of patients with bipolar disorder and schizophrenia. *Biol. Psychiatry* 2005, 57, 525–532.
167. Haitina, T.; Lindblom, J.; Renstrom, T.; Fredriksson, R. Fourteen novel human members of mitochondrial solute carrier family 25 (slc25) widely expressed in the central nervous system. *Genomics* 2006, 88, 779–790.

168. Fiermonte, G.; Paradies, E.; Todisco, S.; Marobbio, C.M.; Palmieri, F. A novel member of solute carrier family 25 (slc25a42) is a transporter of coenzyme a and adenosine 3′,5′-diphosphate in human mitochondria. *J. Biol. Chem.* 2009, 284, 18152–18159.

169. Palmieri, F. The mitochondrial transporter family (slc25): Physiological and pathological implications. *Pflugers Arch.* 2004, 447, 689–709.

170. Zhang, H.; Chen, X.; Sairam, M.R. Novel genes of visceral adiposity: Identification of mouse and human mesenteric estrogen-dependent adipose (meda)-4 gene and its adipogenic function. *Endocrinology* 2012, 153, 2665–2676.

171. Stolzing, A.; Grune, T. Neuronal apoptotic bodies: Phagocytosis and degradation by primary microglial cells. *FASEB J.* 2004, 18, 743–745.

172. Prager-Khoutorsky, M.; Spira, M.E. Neurite retraction and regrowth regulated by membrane retrieval, membrane supply, and actin dynamics. *Brain Res.* 2009, 1251, 65–79.

173. Klein, M.E.; Younts, T.J.; Castillo, P.E.; Jordan, B.A. Rna-binding protein sam68 controls synapse number and local beta-actin mrna metabolism in dendrites. *Proc. Natl. Acad. Sci. USA* 2013, 110, 3125–3130.

174. Ghosh, T.; Soni, K.; Scaria, V.; Halimani, M.; Bhattacharjee, C.; Pillai, B. Microrna-mediated up-regulation of an alternatively polyadenylated variant of the mouse cytoplasmic β-actin gene. *Nucleic Acids Res.* 2008, 36, 6318–6332.

175. Ferreira, E.; Cronje, M.J. Selection of suitable reference genes for quantitative real-time PCR in apoptosis-induced mcf-7 breast cancer cells. *Mol. Biotechnol.* 2012, 50, 121–128.

176. Riviere, J.B.; van Bon, B.W.; Hoischen, A.; Kholmanskikh, S.S.; O’Roak, B.J.; Gilissen, C.; Gijsen, S.; Sullivan, C.T.; Christian, S.L.; Abdul-Rahman, O.A.; et al. De novo mutations in the actin genes actb and actg1 cause baraitser-winter syndrome. *Nat. Genet.* 2012, 44, 440–444.

177. Miwa, T.; Manabe, Y.; Kurokawa, K.; Kamada, S.; Kanda, N.; Bruns, G.; Ueyama, H.; Kakunaga, T. Structure, chromosome location, and expression of the human smooth muscle (enteric type) γ-actin gene: Evolution of six human actin genes. *Mol. Cell. Biol.* 1991, 11, 3296–3306.

178. Kumar, A.; Crawford, K.; Close, L.; Madison, M.; Lorenz, J.; Doetschman, T.; Pawlowski, S.; Duffy, J.; Neumann, J.; Robbins, J.; et al. Rescue of cardiac alpha-actin-deficient mice by enteric smooth muscle gamma-actin. *Proc. Natl. Acad. Sci. USA* 1997, 94, 4406–4411.

179. Li, G.Y.; Kim, M.; Kim, J.H.; Lee, M.O.; Chung, J.H.; Lee, B.H. Gene expression profiling in human lung fibroblast following cadmium exposure. *Food Chem. Toxicol.* 2008, 46, 1131–1137.

180. Marshall, T.W.; Aloor, H.L.; Bear, J.E. Coronin 2a regulates a subset of focal-adhesion-turnover events through the cofillin pathway. *J. Cell Sci.* 2009, 122, 3061–3069.

181. Huang, W.; Ghisletti, S.; Saijo, K.; Gandhi, M.; Aouadi, M.; Tesz, G.J.; Zhang, D.X.; Yao, J.; Czech, M.P.; Goode, B.L.; et al. Coronin 2a mediates actin-dependent de-repression of inflammatory response genes. *Nature* 2011, 470, 414–418.
182. Franco, D.L.; Rezaval, C.; Caceres, A.; Schinder, A.F.; Ceriani, M.F. Ena/vasp downregulation triggers cell death by impairing axonal maintenance in hippocampal neurons. *Mol. Cell. Neurosci.* **2010**, *44*, 154–164.

183. Krause, M.; Leslie, J.D.; Stewart, M.; Lafuente, E.M.; Valderrama, F.; Jagannathan, R.; Strasser, G.A.; Rubinson, D.A.; Liu, H.; Way, M.; *et al.* Lamellipodin, an ena/vasp ligand, is implicated in the regulation of lamellipodial dynamics. *Dev. Cell* **2004**, *7*, 571–583.

184. Klostermann, A.; Lutz, B.; Gertler, F.; Behl, C. The orthologous human and murine semaphorin 6a-1 proteins (sema6a-1/sema6a-1) bind to the enabled/vasodilator-stimulated phosphoprotein-like protein (evl) via a novel carboxyl-terminal zyxin-like domain. *J. Biol. Chem.* **2000**, *275*, 39647–39653.

185. Kubota, K.; Kim, J.Y.; Sawada, A.; Tokimasa, S.; Fujisaki, H.; Matsuda-Hashii, Y.; Ozono, K.; Hara, J. Lrrc8 involved in b cell development belongs to a novel family of leucine-rich repeat proteins. *FEBS Lett.* **2004**, *564*, 147–152.

186. Herrick, S.; Evers, D.M.; Lee, J.Y.; Udagawa, N.; Pak, D.T. Postsynaptic pdml5/enigma homolog binds spar and causes dendritic spine shrinkage. *Mol. Cell. Neurosci.* **2010**, *43*, 188–200.

187. Hussain, N.K.; Yamabhai, M.; Bhakar, A.L.; Metzler, M.; Ferguson, S.S.; Hayden, M.R.; McPherson, P.S.; Kay, B.K. A role for epsin n-terminal homology/ap180 n-terminal homology (enth/anth) domains in tubulin binding. *J. Biol. Chem.* **2003**, *278*, 28823–28830.

188. Romanitan, M.O.; Popescu, B.O.; Spulber, S.; Bajenaru, O.; Popescu, L.M.; Winblad, B.; Bogdanovic, N. Altered expression of claudin family proteins in alzheimer’s disease and vascular dementia brains. *J. Cell. Mol. Med.* **2010**, *14*, 1088–1100.

189. Bruggeman, L.A.; Martinka, S.; Simske, J.S. Expression of tm4sf10, a claudin.emp/pmp22 family cell junction protein, during mouse kidney development and podocyte differentiation. *Dev. Dyn.* **2007**, *236*, 596–605.

190. Laketa, V.; Simpson, J.C.; Bechtel, S.; Wiemann, S.; Pepperkok, R. High-content microscopy identifies new neurite outgrowth regulators. *Mol. Biol. Cell* **2007**, *18*, 242–252.

191. Laumet, G.; Petitprez, V.; Sillaire, A.; Ayral, A.M.; Hansmannel, F.; Chapuis, J.; Hannequin, D.; Pasquier, F.; Scarpini, E.; Galimberti, D.; *et al.* A study of the association between the adam12 and sh3pxd2a (sh3md1) genes and Alzheimer’s disease. *Neurosci. Lett.* **2010**, *468*, 1–2.

192. Harold, D.; Jehu, L.; Turic, D.; Hollingworth, P.; Moore, P.; Summerhayes, P.; Moskvina, V.; Foy, C.; Archer, N.; Hamilton, B.A.; *et al.* Interaction between the adam12 and sh3md1 genes may confer susceptibility to late-onset alzheimer's disease. *Am. J. Med. Genet. B* **2007**, *144B*, 448–452.

193. Malinin, N.L.; Wright, S.; Seubert, P.; Schenk, D.; Griswold-Prenner, I. Amyloid-β neurotoxicity is mediated by fish adapter protein and adam12 metalloprotease activity. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 3058–3063.

194. Levi, G.; Aloisi, F.; Ciotti, M.T.; Gallo, V. Autoradiographic localization and depolarization-induced release of acidic amino acids in differentiating cerebellar granule cell cultures. *Brain Res.* **1984**, *290*, 77–86.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).